Overview

Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma

Status:
Active, not recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

In this trial, monoclonal anti-Disialoganglioside GD2 (GD2) antibody ch14.18/CHO will be assessed for the treatment of patients with relapsed or refractory neuroblastoma. The antibody is used as a single agent applied in a new treatment schedule associated with less side effects.

Phase:

Phase 2

Details

Lead Sponsor:

University Medicine Greifswald

Collaborator:

Children's Cancer Research Institute, Austria

Treatments:

Antibodies
Antibodies, Monoclonal
Dinutuximab